Literature DB >> 15629225

Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies.

Lucy Nooney1, Ruth C Matthews, James P Burnie.   

Abstract

This article reported the identification of heat shock protein 90 (hsp90) homologues by immunoblot in Cryptococcus neoformans. Mycograb, a genetically recombinant antibody against hsp90, was evaluated against 8 clinical isolates and the National External Quality Assessment Service for Microbiology strain of C. neoformans alone and in combination with amphotericin B, caspofungin, and fluconazole by checkerboard assay. At the end point of an optically clear well, the minimum inhibitory concentration (MIC) 0's ranged from 256 to 1024 microg/mL for Mycograb, from 0.5 to 1 microg/mL for amphotericin B, and from 16 to 32 microg/mL for caspofungin. The combination of Mycograb and amphotericin B produced a fractional inhibitory concentration index from 0.27 to 0.56, indicating a mainly synergistic effect, whereas for caspofungin, it varied from 0.5 to 2. At an end point of > or =50% inhibition, the MIC-2s varied from 16 to 128 microg/mL for Mycograb and from 0.125 to 16 microg/mL for fluconazole. The fractional inhibitory concentration index classified the combination as indifferent for 5 isolates, additive for 3 more isolates, and synergistic in a single isolate. Time-kill analysis on 2 isolates (F/7844 and F/10156), which had synergistic and additive results with amphotericin B, respectively, on checkerboard was performed with 4-16 microg/mL of Mycograb, 2-8 microg/mL of fluconazole, and 0.0625-2 microg/mL of amphotericin B. This demonstrated an increasingly static effect with augmenting concentrations of fluconazole and an initial static effect with amphotericin B at lower concentrations, which became fungicidal as the level of drug increased. The addition of either 4 or 8 microg/mL of Mycograb to 0.5 microg/mL of amphotericin B with C. neoformans F/7844 changed a static effect to a fungicidal effect at 8 h with an increased killing of 1.2 logs at 48 h. With C. neoformans F/10156, the addition of 16 microg/mL of Mycograb to 0.25 microg/mL of amphotericin B produced a difference in killing from 1 logarithm after 4 h to 1.5 logarithms after 48 h. These data suggest that the combination of amphotericin B and Mycograb would be worth exploring in the treatment of infection due to C. neoformans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15629225     DOI: 10.1016/j.diagmicrobio.2004.08.013

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  19 in total

Review 1.  An insight into the antifungal pipeline: selected new molecules and beyond.

Authors:  Luis Ostrosky-Zeichner; Arturo Casadevall; John N Galgiani; Frank C Odds; John H Rex
Journal:  Nat Rev Drug Discov       Date:  2010-08-20       Impact factor: 84.694

2.  Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis.

Authors:  Hong Xin; Jim E Cutler
Journal:  Clin Vaccine Immunol       Date:  2011-08-10

3.  Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii.

Authors:  Julliana Ribeiro Alves Santos; Ludmila Ferreira Gouveia; Erika Linzi Silva Taylor; Maria Aparecida Resende-Stoianoff; Gerson Antônio Pianetti; Isabela Costa César; Daniel Assis Santos
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

4.  Nonspecific effect of Mycograb on amphotericin B MIC.

Authors:  D L Richie; M A Ghannoum; N Isham; K V Thompson; N S Ryder
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

Review 5.  Heat Shock Proteins in Histoplasma and Paracoccidioides.

Authors:  Levi G Cleare; Daniel Zamith-Miranda; Joshua D Nosanchuk
Journal:  Clin Vaccine Immunol       Date:  2017-11-06

Review 6.  Cryptococcal therapies and drug targets: the old, the new and the promising.

Authors:  Carolina Coelho; Arturo Casadevall
Journal:  Cell Microbiol       Date:  2016-04-08       Impact factor: 3.715

7.  A proteomic-based approach for the identification of immunodominant Cryptococcus neoformans proteins.

Authors:  Mattie Young; Sandra Macias; Derek Thomas; Floyd L Wormley
Journal:  Proteomics       Date:  2009-05       Impact factor: 3.984

8.  Functions of Antibodies.

Authors:  Donald N Forthal
Journal:  Microbiol Spectr       Date:  2014-08-15

9.  Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens.

Authors:  M A Pfaller; S A Messer; N Georgopapadakou; L A Martell; J M Besterman; D J Diekema
Journal:  J Clin Microbiol       Date:  2009-09-30       Impact factor: 5.948

10.  Fingolimod Potentiates the Antifungal Activity of Amphotericin B.

Authors:  Lu-Qi Wei; Jing-Cong Tan; Yue Wang; Yi-Kun Mei; Jia-Yu Xue; Lei Tian; Ke-Yu Song; Lu Han; Ying-Chao Cui; Yi-Bing Peng; Jing-Quan Li; Ning-Ning Liu; Hui Wang
Journal:  Front Cell Infect Microbiol       Date:  2021-04-23       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.